GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Anastrozole tablets

Local official-label summaryBase record retrieved 2026-09-05See the evidence for this drug2 sources available - open source summaries, references and comparisons

Arimidex

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Official source

Anastrozole tablets - selected U.S. labeling

Product / population
Postmenopausal women with the breast-cancer indications covered by the selected U.S. label; oral anastrozole tablets.
Renal measure
Qualitative renal guidance; no CrCl threshold for dose reduction.
Labeled basic dosing

Give 1 mg orally once daily, with or without food. Duration is indication-specific and should follow the oncology treatment plan.

Renal information and dialysis

The selected U.S. label requires no dose change for renal impairment because renal dysfunction does not materially affect total-body clearance.

Selected warnings and limits

Review bone-density loss and cholesterol effects. Estrogen-containing therapy can oppose the treatment effect; concurrent tamoxifen is not recommended.

Source revision: Label revision date not separately recorded; retrieval date is not the revision date. | Retrieved: 2026-09-05. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=acbfaaa9-503c-4691-9828-76a7146ed6de

Scope: Selected dosing/renal sections read; concise local summary, not full prescribing information. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Official product label

Anastrozole tablets - selected U.S. labeling

Postmenopausal women with the breast-cancer indications covered by the selected U.S. label; oral anastrozole tablets.

Renal method: Qualitative renal guidance; no CrCl threshold for dose reduction.
Retrieved: 2026-09-05

Read local renal resultOpen original reference
Handbook

Renal Drug Handbook, fifth edition - Anastrozole tablets

Historical renal/RRT cross-check for the named ingredient; not a current U.S. prescribing instruction.

Renal method: Book table headings say GFR (mL/min); the preface states adjustment information is based on Cockcroft-Gault CrCl, not indexed eGFR. Do not substitute methods.
Retrieved: 2026-09-05

Read local renal result

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

Handbook source

Renal Drug Handbook, fifth edition - Anastrozole tablets

Historical renal/RRT cross-check for the named ingredient; not a current U.S. prescribing instruction.

Method: Book table headings say GFR (mL/min); the preface states adjustment information is based on Cockcroft-Gault CrCl, not indexed eGFR. Do not substitute methods.

Historical renal and dialysis observationsRead this complete source summary

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeAnastrozole tablets - selected U.S. labelingRenal Drug Handbook, fifth edition - Anastrozole tablets
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=acbfaaa9-503c-4691-9828-76a7146ed6de

Product and population scope

Postmenopausal women with the breast-cancer indications covered by the selected U.S. label; oral anastrozole tablets.

RDM31-anastrozole-scope · Source section: Editorial scope tied to selected U.S. labelRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

Anastrozole tablets - selected U.S. labeling

Open original reference

Open / share this exact local source

U.S. product labeling / DailyMed · Postmenopausal women with the breast-cancer indications covered by the selected U.S. label; oral anastrozole tablets.

Renal method: Qualitative renal guidance; no CrCl threshold for dose reduction.
Source date: Label revision date not separately recorded; retrieval date is not the revision date.
Retrieved: 2026-09-05

Selected dosing/renal sections read; concise local summary, not full prescribing information.

Labeled basic dosing

Give 1 mg orally once daily, with or without food. Duration is indication-specific and should follow the oncology treatment plan.

RDM31-anastrozole-label-dose · Source locator: 2.1

Renal information and dialysis

The selected U.S. label requires no dose change for renal impairment because renal dysfunction does not materially affect total-body clearance.

RDM31-anastrozole-label-renal · Source locator: 8.6 Renal Impairment

Selected warnings and limits

Review bone-density loss and cholesterol effects. Estrogen-containing therapy can oppose the treatment effect; concurrent tamoxifen is not recommended.

RDM31-anastrozole-label-limits · Source locator: 5.2, 5.3; 7.1, 7.2

Source identity and provenance
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=acbfaaa9-503c-4691-9828-76a7146ed6de
Retrieved
2026-09-05
DailyMed Set ID
acbfaaa9-503c-4691-9828-76a7146ed6de
Renal-function method
Qualitative renal guidance; no CrCl threshold for dose reduction.
Source date/version
Label revision date not separately recorded; retrieval date is not the revision date.
Hash meaning
SHA-256 identifies this local summary, not original SPL XML or label PDF.
Local summary SHA-256
bb5ac454e2f3b8c6e2a36d2555552c029d093321aa49b3c99a4ed8baa57f1596
Separate handbook layer

Renal Drug Handbook cross-check

Handbook

Renal Drug Handbook, fifth edition - Anastrozole tablets

Open / share this exact local source

UK Renal Pharmacy Group / CRC Press · Historical renal/RRT cross-check for the named ingredient; not a current U.S. prescribing instruction.

Renal method: Book table headings say GFR (mL/min); the preface states adjustment information is based on Cockcroft-Gault CrCl, not indexed eGFR. Do not substitute methods.
Source date: Fifth edition, 2019
Retrieved: 2026-09-05

Historical source, separately displayed. Renal tables were read with page-image inspection.

Historical renal and dialysis observations

The book retains standard dosing in all three renal bands and its listed dialysis modalities. Its commentary explicitly contrasts U.S. no-reduction advice with an older UK recommendation to avoid use below 20 mL/min.

RDM31-anastrozole-book · Source locator: Dose in renal impairment; renal replacement therapies; Other information

Source-specific limits

That UK restriction is a historical statement in the 2019 book, not a claim about current UK labeling. Do not import it into the U.S. dose rule.

Source identity and provenance
Retrieved
2026-09-05
Handbook page
Printed page(s) 71; PDF page(s) 90
Renal-function method
Book table headings say GFR (mL/min); the preface states adjustment information is based on Cockcroft-Gault CrCl, not indexed eGFR. Do not substitute methods.
Source date/version
Fifth edition, 2019
U.S. product identity basis
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=acbfaaa9-503c-4691-9828-76a7146ed6de
Hash meaning
SHA-256 identifies the local paraphrase; the source PDF is not redistributed.
Local summary SHA-256
8a83f954df7fba60ffd610d56bc8dc1094cae61be2dda9a809aa1155e2d342c9

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 0 RX List, 0 professional, 1 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=acbfaaa9-503c-4691-9828-76a7146ed6de
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
multisource addition
Local text SHA-256
ac63d994d3c0b4ccbc6ef45baf0fac2293c338629d92b6b6b917877facd48323
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report